These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 32644826)
1. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826 [No Abstract] [Full Text] [Related]
2. The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. Kinashi Y; Ikawa T; Takahashi S Appl Radiat Isot; 2020 Sep; 163():109204. PubMed ID: 32561044 [TBL] [Abstract][Full Text] [Related]
3. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477 [TBL] [Abstract][Full Text] [Related]
4. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O Jin L; Kiang KM; Cheng SY; Leung GK Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658 [TBL] [Abstract][Full Text] [Related]
6. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
7. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
8. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
9. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953 [TBL] [Abstract][Full Text] [Related]
10. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186 [TBL] [Abstract][Full Text] [Related]
11. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889 [TBL] [Abstract][Full Text] [Related]
12. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
14. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006 [TBL] [Abstract][Full Text] [Related]
15. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells. Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592 [TBL] [Abstract][Full Text] [Related]
16. Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). Yahyapour R; Khoei S; Kordestani Z; Larizadeh MH; Jomehzadeh A; Amirinejad M; Ahmadi-Zeidabadi M Curr Radiopharm; 2023; 16(2):123-132. PubMed ID: 36503396 [TBL] [Abstract][Full Text] [Related]
17. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829 [TBL] [Abstract][Full Text] [Related]
18. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
19. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365 [TBL] [Abstract][Full Text] [Related]
20. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression. Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]